<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>the akampioneer &#187; Food for Thought</title>
	<atom:link href="http://akampioneer.com/category/food-for-thought/feed" rel="self" type="application/rss+xml" />
	<link>http://akampioneer.com</link>
	<description></description>
	<lastBuildDate>Mon, 14 May 2012 08:00:40 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.1</generator>
		<item>
		<title>Food for Thought: Which Media Are You Reading Most Frequently?</title>
		<link>http://akampioneer.com/food-for-thought/food-for-thought-which-media-are-you-reading-most-frequently.html</link>
		<comments>http://akampioneer.com/food-for-thought/food-for-thought-which-media-are-you-reading-most-frequently.html#comments</comments>
		<pubDate>Wed, 18 Apr 2012 07:20:47 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Food for Thought]]></category>
		<category><![CDATA[akampion]]></category>
		<category><![CDATA[information sources]]></category>
		<category><![CDATA[media usage]]></category>
		<category><![CDATA[poll]]></category>
		<category><![CDATA[social media]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=2631</guid>
		<description><![CDATA[There has been a frenzy about new media and information sources, especially since the emergence of social media like Twitter. Keeping track of all the different media available today is very time-consuming. Which media do you really use? Do you primarily rely on established trade and financial media? Or are you taking advantage of free [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/food-for-thought/food-for-thought-which-media-are-you-reading-most-frequently.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Food for Thought: Crowd-funding &#8211; A Useful Financing Strategy for Healthcare Companies?</title>
		<link>http://akampioneer.com/food-for-thought/food-for-thought-crowd-funding-a-useful-financing-strategy-for-healthcare-companies.html</link>
		<comments>http://akampioneer.com/food-for-thought/food-for-thought-crowd-funding-a-useful-financing-strategy-for-healthcare-companies.html#comments</comments>
		<pubDate>Fri, 23 Mar 2012 09:56:25 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Food for Thought]]></category>
		<category><![CDATA[AMD Therapy]]></category>
		<category><![CDATA[business model]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[crowd sourcing]]></category>
		<category><![CDATA[crowd-funding]]></category>
		<category><![CDATA[crowdfunding]]></category>
		<category><![CDATA[crowdsourcing]]></category>
		<category><![CDATA[drug development]]></category>
		<category><![CDATA[financing model]]></category>
		<category><![CDATA[healthcare]]></category>
		<category><![CDATA[healthcare IT]]></category>
		<category><![CDATA[impact]]></category>
		<category><![CDATA[individual causes]]></category>
		<category><![CDATA[life sciences]]></category>
		<category><![CDATA[medical bills]]></category>
		<category><![CDATA[medtech]]></category>
		<category><![CDATA[microphilanthrophy]]></category>
		<category><![CDATA[patient participation]]></category>
		<category><![CDATA[patients]]></category>
		<category><![CDATA[rare diseases]]></category>
		<category><![CDATA[Rare Genomics Institute]]></category>
		<category><![CDATA[reporting]]></category>
		<category><![CDATA[requirements]]></category>
		<category><![CDATA[Selexel]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[Urodelia]]></category>
		<category><![CDATA[venture philanthrophy]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=2179</guid>
		<description><![CDATA[Crowd-funding is a widely discussed and disputed financing approach these days. It has proven to work in many industries, including the entertainment sector. But what implications will it have for the healthcare industry? Will it have any impact on healthcare at all? So far, there are only few examples of crowd-funded healthcare ventures. One of [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/food-for-thought/food-for-thought-crowd-funding-a-useful-financing-strategy-for-healthcare-companies.html/feed</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
		<item>
		<title>Food for Thought: Greek Ghosts Haunting Pharma</title>
		<link>http://akampioneer.com/food-for-thought/food-for-thought-greek-ghosts-haunting-pharma.html</link>
		<comments>http://akampioneer.com/food-for-thought/food-for-thought-greek-ghosts-haunting-pharma.html#comments</comments>
		<pubDate>Fri, 16 Mar 2012 09:10:32 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Food for Thought]]></category>
		<category><![CDATA[AMNOG]]></category>
		<category><![CDATA[drug assessement]]></category>
		<category><![CDATA[drug pricing]]></category>
		<category><![CDATA[Federal Joint Committee]]></category>
		<category><![CDATA[G-BA]]></category>
		<category><![CDATA[Gemeinsamer Bundesausschuss]]></category>
		<category><![CDATA[Germany's drug pricing system]]></category>
		<category><![CDATA[Germany's statutory healthcare system]]></category>
		<category><![CDATA[Institute for Quality and Efficiency in Health Care]]></category>
		<category><![CDATA[IQW]]></category>
		<category><![CDATA[Law on the Stabilization and Structural Reform of the Statutory Health Insurance]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=2413</guid>
		<description><![CDATA[Up to the end of 2010, pharma companies were able to set the price for innovative new medicine at will upon introduction to the German market. Under the new AMNOG law, however, the price is dependent on the degree of innovation, as assessed by G-BA (Federal Joint Committee). G-BA requires pharma and biotech companies to [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/food-for-thought/food-for-thought-greek-ghosts-haunting-pharma.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Food for Thought: The Indian Biotechnology Industry &#8211; Opportunities for Europe</title>
		<link>http://akampioneer.com/food-for-thought/food-for-thought-the-indian-biotechnology-industry-opportunities-for-europe.html</link>
		<comments>http://akampioneer.com/food-for-thought/food-for-thought-the-indian-biotechnology-industry-opportunities-for-europe.html#comments</comments>
		<pubDate>Tue, 28 Feb 2012 08:55:15 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Food for Thought]]></category>
		<category><![CDATA[Amal Mukhopadhyay]]></category>
		<category><![CDATA[Association of Biotechnology Led Enterprises]]></category>
		<category><![CDATA[bioinformatics]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[Biospectrum]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[ELGA Biotech]]></category>
		<category><![CDATA[IGEP Foundation]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indo-German Chamber of Commerce]]></category>
		<category><![CDATA[manufacturing]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=2242</guid>
		<description><![CDATA[By Dr. Amal Mukhopadhyay The Indian biotechnology industry is growing at record speed, both in terms of turnover and investments. While Indian biotech is recognized in the West  for high quality services, bioinformatics and manufacturing, it also offers great opportunities for conducting clinical trials and manufacturing of biosimilars. Only recently, European companies have started to [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/food-for-thought/food-for-thought-the-indian-biotechnology-industry-opportunities-for-europe.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Food for Thought: Future Benefit Assessment of Medtech in Germany</title>
		<link>http://akampioneer.com/food-for-thought/food-for-thought-future-benefit-assessment-of-medtech-in-germany.html</link>
		<comments>http://akampioneer.com/food-for-thought/food-for-thought-future-benefit-assessment-of-medtech-in-germany.html#comments</comments>
		<pubDate>Mon, 20 Feb 2012 10:09:59 +0000</pubDate>
		<dc:creator>akampion</dc:creator>
				<category><![CDATA[Food for Thought]]></category>
		<category><![CDATA[BVMed]]></category>
		<category><![CDATA[G-BA]]></category>
		<category><![CDATA[German Medical Technology Association]]></category>
		<category><![CDATA[Institute for Quality and Efficiency in Health Care]]></category>
		<category><![CDATA[IQWiG]]></category>
		<category><![CDATA[Joint Federal Committee]]></category>
		<category><![CDATA[Law on the Stabilization and Structural Reform of the Statutory Health Insurance]]></category>
		<category><![CDATA[medtech]]></category>
		<category><![CDATA[Rainer Hess]]></category>
		<category><![CDATA[trial provision]]></category>
		<category><![CDATA[Versorgungsstrukturgesetz]]></category>

		<guid isPermaLink="false">http://akampioneer.com/?p=2145</guid>
		<description><![CDATA[Germany´s Law on the Stabilization and Structural Reform of the Statutory Health Insurance (Versorgungsstrukturgesetz) came into effect January 1st, 2012. For medtech companies it is important that the law introduces a novel instrument of the statutory healthcare system&#8217;s Joint Federal Committee G-BA for the assessment of innovative medical technologies. This novelty &#8211; the so-called &#8220;trial [...]]]></description>
		<wfw:commentRss>http://akampioneer.com/food-for-thought/food-for-thought-future-benefit-assessment-of-medtech-in-germany.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

